Evidence map›Paper›PMID 25755504›Full record

ReviewJournal of clinical and experimental hepatology2013

Hepatitis E and Acute-on-Chronic Liver Failure.

Ashish Kumar, Vivek A Saraswat

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical and experimental hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06457438 (Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors), which is not on this map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06457438 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors

TypeinterventionalSponsorUniversity Hospital OstravaRan2022 to 2024Enrolled300ConditionsHepatitis EArmsElecsys Anti-HEV IgG, IgM
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Acute HEV Infection Is a Relevant Cause of Decompensation and ACLF in Patients With Liver Cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Observational
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Hepatitis E as a trigger for acute-on-chronic liver failure.Clinical and molecular hepatology · 2025
    Review
  9. Hepatitis E vaccination: the promise of prevention.Proceedings (Baylor University. Medical Center) · 2025
    Article
  10. Modeling extrahepatic hepatitis E virus infection in induced human primary neurons.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  11. Review
  12. [Intrahepatic and extrahepatic clinical manifestations and treatment progress for hepatitis type E].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Article
  13. Review
  14. Treatment of Hepatitis E.Advances in experimental medicine and biology · 2023
    Article
  15. Clinical Manifestations of Hepatitis E.Advances in experimental medicine and biology · 2023
    Article
  16. Nosocomial transmission of hepatitis E virus and development of chronic infection: The wider impact of COVID-19.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Ashish KumarDepartment of Gastroenterology & Hepatology, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi 110 060, India.
Vivek A SaraswatDepartment of Gastroenterology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh 226014, India.
Sanjay Gandhi Post Graduate Institute of Medical Sciences · INSir Ganga Ram Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis (AVH) globally. It causes large scale epidemics of AVH across the low- and middle income countries in Asia and Africa, and also causes sporadic cases of AVH in the same geographical region. AVH due to HEV is usually an acute, self-limiting illness, similar in clinical presentation to AVH caused by hepatitis A virus (HAV). When HEV causes AVH in patients of chronic liver disease it may worsen rapidly to a syndrome called acute-on-chronic liver failure (ACLF) leading to very high mortality. Acute deterioration of liver function in a patient with compensated chronic liver disease is the characteristic feature of ACLF. The typical disease course of patients with ACLF is the appearance of organ failure, which progresses to multi-organ failure and death. Many publications have reported HEV as one of the leading causes for ACLF from Asia and Africa, where HEV is endemic. The mortality rate of HEV-related ACLF (HEV-ACLF) ranges from 0% to 67% with a median being 34%. These patients require admission in the intensive care unit and they benefit from a team approach of clinicians with expertise in both hepatology and critical care. The goals of treatment are to prevent further deterioration in liver function, reverse precipitating factors, and support failing organs. Liver transplantation is required in selected patients to improve survival and quality of life. One preliminary report suggests that ribavirin may be an effective and safe drug for treatment of HEV-ACLF however this requires validation in large trials.

Indexed as

ACLF, acute-on-chronic liver failureacute-on-chronic liver failureAPASL, Asia–Pacific Association for the Study of LiverAVH, acute viral hepatitisCHB, chronic hepatitis BcirrhosisHAV, hepatitis A virusHBV, hepatitis B virushepatitis E virusHEV-ACLF, HEV-related ACLFHEV, hepatitis E virusICU, intensive care unitINR, international normalized ratioliver failureMELD, model for end-stage liver diseaseribavirin

Identifiers

PMID25755504
PMCPMC3940130
OpenAlexW2004025528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.